Development and Commercialization Plans. (a) Consistent with Section 4.1: (i) Licensee shall prepare and provide ▇▇▇▇▇ with a development plan (“Development Plan”) for each Specified Disease within the Field. Each Development Plan shall set forth anticipated activities, plans and timelines for the development of Licensed Products targeting the relevant Specified Disease (including regulatory timelines for each Major Country). Following initial submission, each Development Plan shall be updated by Licensee at least annually for each Specified Disease in the Field. Annual updates shall include a description of all significant activities and results since the date of the most recent Development Plan. An initial Development Plans for each Specified Disease included in the Field shall be delivered not later than one hundred eighty (180) days prior to the date upon which Licensee in good faith anticipates Phase I Clinical Trials will begin for the Specified Disease. (ii) Licensee shall provide ▇▇▇▇▇ with a commercialization plan (“Commercialization Plan”) for each Licensed Product no later than one (1) year prior to the anticipated First Commercial Sale of the Licensed Product in a Major Country. Each Commercialization Plan shall set forth projected annual Net Sales and anticipated activities, plans and timelines for the commercialization of the relevant Licensed Product. Each Development Plan and Commercialization Plan shall be prepared by Licensee in good faith and shall reflect Licensee’s intentions and projection as of the date of its delivery to ▇▇▇▇▇.
Appears in 2 contracts
Sources: Non Exclusive License Agreement (Coley Pharmaceutical Group, Inc.), Non Exclusive License Agreement (Coley Pharmaceutical Group, Inc.)